Shanghai, Suzhou, 4 June, 2021--Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO), to be held in a virtual format from June 4 to 8, 2021.
The Trials in Progress poster presentation summarizes the safety profile, antitumor activity observed in a phase I clinical trial (NCT04130542) in collaboration with Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada. The trial is evaluating LVGN6051, a second generation 4-1BB (CD137) agonist antibody based on Lyvgen proprietary xLinkAb platform, as monotherapy or in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in adult patients with advanced malignancies. No MTD was reached at 7 mg/kg monotherapy and 4 mg/kg q3w monotherapy was determined as RP2D. Preliminary antitumor activity in late stage cancer patients was observed. Combination with pembrolizumab induced rapid antitumor responses in advanced cancer patients with immune-cold tumor or relapsed from prior immunotherapies.
February 23, 2021 - Lyvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it has completed Series C founding. This round of financing was led by IDG Capital and included Shanghai FTZ Fund, Suzhou Longmen Venture Capital, CHENGWEI Capital and others, with China Renaissance Group as the exclusive financial adviser.
January 26, 2021 - Lyvgen, a clinical-stage biotechnology company, today announced first-in-human (FIH) dosing of its xLinkAb product LVGN7409 (CD40 agonist), a bi-functional monoclonal antibody optimally activating CD40 upon FcγRIIB-mediated cross-linking.
January 26, 2021
Suzhou, China, October 19, 2020 – Lyvgen Biopharma, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, is pleased to announce today the appointment of Xiaofeng Liu, Ph.D. as Senior Vice President of Manufacturing & Drug Development. This appointment forms part of Lyngen’s strategic drive to strengthen CMC capabilities including GMP manufacturing.
October 19, 2020
Lyvgen Biopharma (Suzhou) officially opened in BioBAY on June 10, 2020. Founded by Dr. Jieyi Wang in 2016, Lyvgen focuses on the development of novel immune-oncology (IO) agonist antibodies. At present, the company has built an CMC center of 2,000 square meters of therapeutic antibodies in BioBAY, Suzhou, China. The company headquarters, R&D center and GMP production site are also under active preparation. Follow us on Linkedlin.
June 10, 2020
Lyvgen announced, through its fully owned subsidiary Lyvgen Biopharma (Suzhou), the successful GMP-compliant production of LVGN7409
Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy